**Table 2. Patient Disease and Treatment Characteristics (N=100)**

|  |  |
| --- | --- |
| **Diagnosis** |  |
| Malignancy\* | 73% (73) |
| Premalignancy † | 9% (9) |
| Benign ‡ | 12% (12) |
| Osteoradionecrosis | 3% (3) |
| Diagnosis Pending | 3% (3) |
| **Primary Site** |  |
| Skin | 16% (16) |
| Oral Cavity | 33% (33) |
| Nasopharynx | 1% (1) |
| Oropharynx | 25% (25) |
| Larynx | 7% (7) |
| Thyroid & Parathyroid | 2% (2) |
| Salivary Gland | 11% (11) |
| Other | 5% (5) |
| **Treatment (all diagnoses)** |  |
| Nonsurgical | 5% (5) |
| Pre-operative/Pre-treatment | 12% (12) |
| Surgery alone | 40% (40) |
| Surgery followed by adjuvant radiation +/-  chemotherapy | 32% (32) |
| Primary Chemoradiation therapy alone | 5% (5) |
| Salvage surgery | 4% (4) |
| Other | 1% (2) |
| **Treatment Time course (Malignancies only n=73)** |  |
| Completed treatment | 54% (54) |
| Active treatment | 13% (13) |
| Awaiting treatment | 6% (6) |

\*Included Squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, melanoma, nonhodgkin’s lymphoma, carcinoma ex pleomorphic adenoma, mucoepidermoid carcinoma, acinic cell carcinoma, adenoid cystic carcinoma, pleomorphic sarcoma, angiosarcoma, sebaceous carcinoma

†Included oral leukoplakia and dysplasia

‡Included biopsy for lesions to rule out malignancy, pituitary adenoma, parathyroid adenoma, schwannoma, thyroid goiter, pleomorphic adenoma, globus sensation, chronic tonsillitis, odontogenic keratocyst, sialolith